Peer-influenced content. Sources you trust. No registration required. This is HCN.
MedCentral
The new chemical entity is an atypical antipsychotic and the active metabolite of iloperidone (Fanapt). Its ability to cross the blood-brain barrier likely contributes to iloperidone’s clinical effects.
Psychiatry March 4th 2026
Psychiatrist.com
The objective of the study was to characterize the real-world safety profile of TMS devices based on MAUDE-reported AEs, including symptom patterns, manufacturer-level variations, device issues, and reporting delays.
Psychiatry Advisor
The study authors noted that DBT was more effective than SSRI/M for reducing suicide-related and self-injurious behaviors during the 6-month treatment phase, though differences were not sustained at 12 months.
Journal of Attention Disorders (JAD)
“Women and girls are too often suffering in silence, being left out of the ADHD narrative.” — Attoe & Climie, Journal of Attention Disorders, 2023
Psych Congress Network
“TRD patients have extremely limited treatment options, and the unmet need remains profound.” — Guy Goodwin, MD, CMO, Compass Pathways
Medical Xpress
“It’s not a case of cannabis being all good or all bad. It depends on how people are using it, what outcomes you’re looking at, what products are being used, for what reasons, and what part of the lifespan.” — Anika Guha, Ph.D., CU Anschutz
Psychiatry February 18th 2026